Sarizotan (EMD-128,130) is a selective 5-HT_1A receptor agonist and D₂ receptor antagonist, which has

antipsychotic Antipsychotics, also known as neuroleptics, are a class of psychotropic medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia but also in a range of ...

effects, and has also shown efficacy in reducing

dyskinesia Dyskinesia refers to a category of movement disorders that are characterized by involuntary muscle movements, including movements similar to tics or chorea and diminished voluntary movements. Dyskinesia can be anything from a slight tremor of ...

s resulting from long-term anti-Parkinsonian treatment with levodopa. In June 2006, the developer

Merck KGaA The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and present in 66 countries. The group includes around 250 companies; the ma ...

announced that the development of sarizotan was discontinued, after two sarizotan Phase III studies (PADDY I, PADDY II) failed to meet the primary efficacy endpoint and neither the Phase II findings nor the results from preclinical studies could be confirmed. No statistically significant difference of the primary target variable between sarizotan and placebo could be demonstrated.

References

5-HT1A agonists 5-HT7 agonists Abandoned drugs Amines D2 antagonists Pyridines Secondary amines Fluoroarenes Chromanes {{nervous-system-drug-stub

See also

References